Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-GBM-1 in Newly Diagnosed Glioblastoma
NCT05100641Phase 3Not yet recruiting
- Sponsor
- AIVITA Biomedical, Inc.
- Start
- Jan 2024
- Primary completion
- Mar 2028
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 3 trial of AV-GBM-1 in glioblastoma (GBM), sponsored by AIVITA Biomedical, Inc.. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
AV-GBM-1
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05100641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100641.